Nutra Pharma Announces Completion of Clinical Study in Adrenomyeloneuropathy (AMN)
Posted on: Tuesday, 29 July 2008, 09:01 CDT
Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis, has announced today that its wholly-owned drug discovery subsidiary, ReceptoPharm, Inc., has successfully completed the Phase IIb/IIIa clinical trial of its leading drug candidate for neurological and autoimmune disorders, RPI-78M, as a treatment for Adrenomyeloneuropathy (AMN).
"Completing this clinical trial is an important achievement for both Nutra Pharma and ReceptoPharm," commented Paul Reid, CEO of ReceptoPharm. "Our next step is to compile, analyze and present the results from this trial to the medical community," he concluded.
Adrenomyeloneuropathy (AMN) is a rare inherited metabolic disorder that affects approximately 30,000 people worldwide. The disorder is characterized by the loss of the fatty covering (myelin sheath) on nerve fibers within the brain (cerebral demyelination) and the progressive degeneration of the adrenal gland (adrenal atrophy). Neurological disability in AMN is slowly progressive over several decades.
AMN interests the wider neurologic community because of its similarities to Multiple Sclerosis (MS). There is currently no approved treatment for AMN. Additionally, the disease's rarity designates it as an orphan drug candidate both in Europe and in the U.S. The Company has applied for Orphan drug status in the U.S. and intends doing so for the EU.
"Once the data from this trial has been presented, we will continue to expand ReceptoPharm's clinical development program," explained Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. "Currently, we are planning several additional clinical trials, including those for the treatment of Multiple Sclerosis using RPI-78M and the treatment of Rabies and HIV using RPI-MN," he added.
ReceptoPharm expects to present the clinical findings from the study by the end of September.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
http://www.NutraPharma.com
http://www.ReceptoPharm.com
SEC Disclaimer
This press release contains forward-looking statements. The words or phrases "would be,""will allow,""intends to,""will likely result,""are expected to,""will continue,""is anticipated,""estimate,""project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The completion of ReceptoPharm's Phase IIb/IIIa clinical trial for treating Adrenomyeloneuropathy should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
Source: Business Wire
Related Articles
- Affymetrix Launches World's Most Comprehensive Solution for Clinical Drug Metabolism Studies
- Samaritan Therapeutics Signs Research Collaboration and Licensing Agreement With The Research Institute of McGill University Health Centre; Collaboration to Advance Pipeline Into Clinical Trials and Develop New Innovative Drugs
- A.P. Pharma Licenses APF530 to RHEI Pharmaceuticals for Development in Greater China
- Phase II Clinical Data for Predix's Lead Drug Candidate Show Positive Results in Generalized Anxiety Disorder; Results Presented at 46th Annual New Clinical Drug Evaluation Unit Meeting Show Efficacy in Anxiety Patients With Minimal Side Effects
- Ablation better than drugs for arrhythmia: trial
- WHO seeks greater openness in clinical drug trials
- WayPoint Biomedical Launches New Range of Clinical Drugs of Abuse Rapid Tests
- Novagali Pharma Completes EUR26 Million Financing to Support Phase III Clinical Trials and Development of New Ophthalmic Products
- Sino-US Research Centre for Clinical Drugs Set Up in Chinese Capital
- Rockville-Based EntreMed Inc. Obtains Two New Patents for Its Lead Clinical Drug Candidate
 |
 |
User Comments (0)
RSS Feeds